Cardiff Oncology to Present at Upcoming Investor Conferences in September

Ein Business-Meeting (Symbolbild). © gilaxia / E+ / Getty Images

PR Newswire

SAN DIEGO, Sept. 5, 2023

SAN DIEGO, Sept. 5, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced that company management will present at the Baird Global Healthcare Conference on September 12, 2023 and the H.C. Wainwright 25^th Annual Global Investment Conference on September 13, 2023.

Details of the presentations can be found below.

Baird Global Healthcare Conference [only available to live participants]
Location: InterContinental New York Barclay
Presenter: Mark Erlander, CEO
Format: Fireside Chat
Date: 09/12/2023
Time: 9:05 AM ET

H.C. Wainwright 25^th Annual Global Investment Conference
Location: Lotte New York Palace Hotel
Presenter: Mark Erlander, CEO
Format: Company Presentation
Date: 09/13/2023
Time: 11:30 AM ET

Interested parties can register for and access the live webcast for H.C. Wainwright by visiting the "Events" section of the Cardiff Oncology website. The webcast replay will be available after the conclusion of the presentation.

About Cardiff Oncology, Inc.

ARIVA.DE Börsen-Geflüster

Kurse

Cardiff Oncology

4,20 €

0,00%

Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard-of-care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma (mPDAC), as well as in investigator-initiated trials in triple negative breast cancer (TNBC) and small cell lung cancer (SCLC). These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https://www.cardiffoncology.com.

Cardiff Oncology Contact:
James Levine
Chief Financial Officer
858-952-7670
jlevine@cardiffoncology.com

Investor Contact:
Kiki Patel, PharmD
Gilmartin Group
332-895-3225
Kiki@gilmartinir.com

Media Contact:
Richa Kumari
Taft Communications
551 344-5592 
richa@taftcommunications.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/cardiff-oncology-to-present-at-upcoming-investor-conferences-in-september-301916201.html

SOURCE Cardiff Oncology, Inc.

Mehr Nachrichten zur Cardiff Oncology Aktie kostenlos abonnieren

E-Mail-Adresse

Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.